Please login to the form below

ribociclib

This page shows the latest ribociclib news and features for those working in and with pharma, biotech and healthcare.

Novartis highlights emerging assets and late-stage pipeline at R&D day

It also has plans to expand wet AMD therapy Beovu(brolucizumab-dbll) and HER-2 breast cancer treatments Piqray (alpelisib) and Kisqali(ribociclib) into additional indications to help drive growth.

Latest news

Lilly boosted by survival data for key growth drug Verzenio

However, shortly after the top-line data were announced, Novartis reported results with a trial of its rival CDK4/6 inhibitor Kisqali (ribociclib) which stole some of Lilly’s thunder.
Novartis raises 2019 guidance as new products gather speed

from new prostate cancer therapy Lutathera, Kisqali (ribociclib) for breast cancer and CAR-T Kymriah (tisagenlecleucel).
Solid Q1 results lift Pfizer as it waits for pipeline boost

The CDK 4/6 inhibitor looks set to remain one of Pfizer’s biggest growth brands – despite competition from rival products such as Lilly’s Verzenio (abemaciclib) and Kisqali (ribociclib) from
NICE says no to Novartis’ Kisqali combo in breast cancer

Draft guidance from the cost-effectiveness watchdog has concluded CDK 4/6 inhibitor Kisqali (ribociclib) plus fulvestrant should not be offered routinely on the NHS in England for patients with hormone ... More data may address the uncertainties in the
NICE nod for Lilly’s breast cancer drug Verzenio via CDF

The approval sets Verzenio up as a second-line option after other drugs in the CDK 4/6 inhibitor class – including Verzenio itself as well as Novartis’ Kisqali (ribociclib) and ... $6bn product at peak by EvaluatePharma – as well as Novartis’

More from news
Approximately 4 fully matching, plus 31 partially matching documents found.

Latest appointments

Ipsen boosts specialty care and R&D leadership teams

East. Most recently, Semerjian served as senior vice president and global launch head of ribociclib.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Graduate / Entry Level Opportunities – Medical Communications – ...: Highly Competitive Remuneration Package

Account Manager / Senior Account Manager - Creative MedComms - C...: Excellent Remuneration

Senior Medical Writer: Salary TBC

Programme Manager / Programme Director – Medical Education - Buc...: Salary TBC

Account Director – Cheshire based Medical Communications Agency...: D.O.E

Experienced / Senior Medical Writer - MedComms - Cardiff - Wales: Excellent Salary and Benefits on offer

Scientific Director - Medical Communications Agency - New York: Excellent Remuneration Package

Senior Medical Writer – Leading Medical Communications Agency – ...: Highly Competitive Remuneration Package

Senior / Principal Medical Writer – Medical Education - UK &...: Excellent Salary and Benefits on offer

Senior Medical Writer– Medical Education – Oxford - London: Excellent Remuneration Package

Scientific Director - Medical Education - Cheshire & London ...: Excellent Remuneration Package

Associate Medical Writer / Entry Level Medical Writer - Medical ...: DOE

Account Director, Healthcare Communications Agency: £54, 000- £60, 000

Account Director, Medical Education: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

Five key trends in precision and personalised healthcare: Here, we deep dive into five of the key trends in precision medicine and personalised healthcare to explore how the healthcare industry is changing and how pharmaceutical and biotech companies...
OPEN Health Graduate Programme: from OPEN VIE to OPEN Health Medical Communications: Isobel Owens shares her experience of the OPEN Health Graduate Programme from OPEN VIE to OPEN Health Medical Communications...
Language barriers: Obesity has become a loaded word: ...